studies

breast cancer - HER2-positive, lapatinib plus trastuzumab vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsEGF104900, 2010 0.74 [0.57; 0.96] 0.74[0.57; 0.96]EGF104900, 201010%291NAnot evaluable deaths (OS) (extension)detailed resultsALTTO (T plus L vs T), 2020 0.86 [0.70; 1.06] 0.86[0.70; 1.06]ALTTO (T plus L vs T), 202010%4,190NAnot evaluable progression or deaths (PFS)detailed resultsEGF104900, 2010 0.74 [0.58; 0.94] 0.74[0.58; 0.94]EGF104900, 201010%296NAnot evaluable RFS/DFSdetailed resultsALTTO (T plus L vs T), 2020 0.84 [0.70; 1.01] 0.84[0.70; 1.01]ALTTO (T plus L vs T), 202010%4,190NAnot evaluable objective responses (ORR)detailed resultsEGF104900, 2010 1.56 [0.68; 3.59] 1.56[0.68; 3.59]EGF104900, 201010%296NAnot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-05-17 22:18 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 336,147,145,355,337,146,317 - treatments: 1302

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons